

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding
Mangalam Drugs & Organics Awarded US$ 274,800 Grant by MMV
Details : The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.
Product Name : Pyramax
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding

Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Sanaria | University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Malaria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 01, 2022
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Sanaria | University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Richmond Pharmacology | PharmaKinetic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology | PharmaKinetic
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Malaria, Falciparum.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2019
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Cohort Event Monitoring Study of Pyramax®
Details : Pyronaridine Tetraphosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Malaria, Falciparum.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable


 
															 Reset All
Reset All